These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14735404)

  • 1. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.
    Slobod KS; Lockey TD; Howlett N; Srinivas RV; Rencher SD; Freiden PJ; Doherty PC; Hurwitz JL
    Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):106-10. PubMed ID: 14735404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
    Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
    PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.
    Cooney EL; Collier AC; Greenberg PD; Coombs RW; Zarling J; Arditti DE; Hoffman MC; Hu SL; Corey L
    Lancet; 1991 Mar; 337(8741):567-72. PubMed ID: 1671940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic responses to vaccinia vaccines administered by different parenteral routes.
    McClain DJ; Harrison S; Yeager CL; Cruz J; Ennis FA; Gibbs P; Wright MS; Summers PL; Arthur JD; Graham JA
    J Infect Dis; 1997 Apr; 175(4):756-63. PubMed ID: 9086127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein.
    Dallo S; Maa JS; Rodriguez JR; Rodriguez D; Esteban M
    Virology; 1989 Nov; 173(1):323-9. PubMed ID: 2510402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
    Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
    J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of a recombinant vaccinia virus in vaccinia-immune mice.
    Andrew ME
    Immunol Cell Biol; 1989 Oct; 67 ( Pt 5)():339-41. PubMed ID: 2613281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
    Kantor J; Irvine K; Abrams S; Snoy P; Olsen R; Greiner J; Kaufman H; Eggensperger D; Schlom J
    Cancer Res; 1992 Dec; 52(24):6917-25. PubMed ID: 1458480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine.
    McClain DJ; Summers PL; Harrison SA; Schmaljohn AL; Schmaljohn CS
    J Med Virol; 2000 Jan; 60(1):77-85. PubMed ID: 10568767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
    Viner KM; Girgis N; Kwak H; Isaacs SN
    Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant vaccinia-rabies virus in the immunocompromised host: oral innocuity, progressive parenteral infection, and therapeutics.
    Hanlon CA; Niezgoda M; Shankar V; Niu HS; Koprowski H; Rupprecht CE
    Vaccine; 1997 Feb; 15(2):140-8. PubMed ID: 9066030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.
    Cho MW; Kim YB; Lee MK; Gupta KC; Ross W; Plishka R; Buckler-White A; Igarashi T; Theodore T; Byrum R; Kemp C; Montefiori DC; Martin MA
    J Virol; 2001 Mar; 75(5):2224-34. PubMed ID: 11160726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
    Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.
    Thippeshappa R; Tian B; Cleveland B; Guo W; Polacino P; Hu SL
    Clin Vaccine Immunol; 2015 Dec; 23(3):204-12. PubMed ID: 26718849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.
    Barouch DH; Santra S; Kuroda MJ; Schmitz JE; Plishka R; Buckler-White A; Gaitan AE; Zin R; Nam JH; Wyatt LS; Lifton MA; Nickerson CE; Moss B; Montefiori DC; Hirsch VM; Letvin NL
    J Virol; 2001 Jun; 75(11):5151-8. PubMed ID: 11333896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C; McLain L; Dimmock NJ
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peroral immunization--a method for enhancing the safety of the recombinant vector (the vaccinia virus)].
    Podkuĭko VN; Vorob'ev AA; Krasnianskiĭ VP; Patrikeev GT; Mikhaĭlov VV; Dorokhina TV; Makhlaĭ AA; Dykanov GA
    Vestn Ross Akad Med Nauk; 1993; (2):39-44. PubMed ID: 7688619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.